MAIA Biotechnology, Inc. (MAIA) Insider Trading Activity

AMEX$1.54
Market Cap
$57.03M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
177 of 883
Rank in Industry
106 of 506

MAIA Insider Trading Activity

MAIA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$634,789
19
100
Sells
$0
0
0

Related Transactions

Smith Standirector
8
$301,620
0
$0
$301,620
Vitoc VladChief Executive Officer
5
$101,540
0
$0
$101,540
Louie Ngar Yeedirector
1
$100,000
0
$0
$100,000
Luput Cristiandirector
3
$51,631
0
$0
$51,631
CHAOUKI STEVEN Mdirector
1
$49,999
0
$0
$49,999
Guerrero Ramirodirector
1
$30,000
0
$0
$30,000

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Insider Activity of MAIA Biotechnology, Inc.

Over the last 12 months, insiders at MAIA Biotechnology, Inc. have bought $634,789 and sold $0 worth of MAIA Biotechnology, Inc. stock.

On average, over the past 5 years, insiders at MAIA Biotechnology, Inc. have bought $1.57M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Smith Stan (director) — $301,620. Vitoc Vlad (Chief Executive Officer) — $101,540. Louie Ngar Yee (director) — $100,000.

The last purchase of 57,189 shares for transaction amount of $69,999 was made by Smith Stan (director) on 2025‑12‑22.

List of Insider Buy and Sell Transactions, MAIA Biotechnology, Inc.

2025-12-22PurchaseSmith Standirector
57,189
0.1421%
$1.22
$69,999
+45.68%
2025-12-22PurchaseLouie Ngar Yeedirector
81,699
0.203%
$1.22
$100,000
+45.68%
2025-12-22PurchaseCHAOUKI STEVEN Mdirector
40,849
0.1015%
$1.22
$49,999
+45.68%
2025-12-05PurchaseSmith Standirector
13,740
0.0375%
$1.20
$16,441
+38.33%
2025-11-28PurchaseVitoc VladChief Executive Officer
50,000
0.1301%
$1.14
$56,830
+38.56%
2025-11-28PurchaseLuput Cristiandirector
18,145
0.0463%
$1.11
$20,230
+38.56%
2025-11-26PurchaseSmith Standirector
15,000
0.0384%
$1.04
$15,582
+53.77%
2025-11-26PurchaseVitoc VladChief Executive Officer
22,000
0.0568%
$1.05
$23,019
+53.77%
2025-11-26PurchaseLuput Cristiandirector
20,000
0.0533%
$1.08
$21,616
+53.77%
2025-11-25PurchaseSmith Standirector
15,000
0.0435%
$0.98
$14,700
+68.06%
2025-11-25PurchaseVitoc VladChief Executive Officer
10,500
0.0301%
$0.97
$10,144
+68.06%
2025-11-25PurchaseLuput Cristiandirector
10,000
0.029%
$0.98
$9,785
+68.06%
2025-11-24PurchaseSmith Standirector
10,000
0.0293%
$0.99
$9,900
+64.81%
2025-11-24PurchaseVitoc VladChief Executive Officer
10,000
0.0293%
$0.99
$9,891
+64.81%
2025-11-21PurchaseVitoc VladChief Executive Officer
1,800
0.0049%
$0.92
$1,656
+77.18%
2025-10-01PurchaseSmith Standirector
19,230
0.0492%
$1.30
$24,999
-9.64%
2025-06-03PurchaseSmith Standirector
33,333
0.0943%
$1.50
$50,000
-9.71%
2025-05-08PurchaseSmith Standirector
66,666
0.1724%
$1.50
$99,999
-17.86%
2025-05-08PurchaseGuerrero Ramirodirector
20,000
0.0517%
$1.50
$30,000
-17.86%
2025-03-03PurchaseSmith Standirector
25,000
0.0841%
$1.50
$37,500
-4.12%
Total: 133
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Smith Standirector
1421478
3.8385%
$2.19M520
<0.0001%
Louie Ngar Yeedirector
1248888
3.3724%
$1.92M50
+6.58%
Vitoc VladChief Executive Officer
903421
2.4395%
$1.39M260
<0.0001%
Guerrero Ramirodirector
588218
1.5884%
$905,855.72200
<0.0001%
Luput Cristiandirector
437628
1.1817%
$673,947.12210
<0.0001%
CHAOUKI STEVEN Mdirector
151873
0.4101%
$233,884.4240
+3.42%
Vlad Laurentiu
376933
1.0178%
$580,476.8210
<0.0001%
Obrocea MihailChief Medical Officer
27100
0.0732%
$41,734.0010
<0.0001%
Gryaznov SergeiChief Scientific Officer
24511
0.0662%
$37,746.9410
<0.0001%
MCGUIRE JOSEPH FChief Financial Officer
9400
0.0254%
$14,476.0020
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

MAIA Biotechnology, Inc.
(MAIA)
$5,354,267
110
-35.34%
$57.03M
$1,695,621
55
17.90%
$59.7M
$103,288,323
51
4.78%
$50.39M
$693,326
47
-16.18%
$48.34M
$24,478,755
37
-34.59%
$49.82M
$27,151,286
27
-16.85%
$63.56M
$226,127
22
-27.62%
$54.43M
$1,602,584
20
15.26%
$66.84M
$3,763,566
15
-21.70%
$61.11M
$277,862
15
59.79%
$57.32M
$39,336,371
14
-17.87%
$57.61M
$19,300,035
11
45.88%
$50.82M
$32,684,649
8
-15.84%
$69.98M
$45,000,000
6
-31.22%
$60.16M
$762,555
4
-34.52%
$67.32M
$657,791
4
-52.05%
$48.99M
$67,369,250
3
-22.09%
$48.91M
$12,498
2
39.61%
$48.77M
$4,030
1
9.14%
$53.08M

MAIA Institutional Investors: Active Positions

Increased Positions17+130.77%257,493+10.85%
Decreased Positions2-15.38%114,493-4.82%
New Positions9New162,183New
Sold Out Positions2Sold Out114,493Sold Out
Total Postitions28+115.38%3M+6.02%

MAIA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$1,765.002.98%1.1M-37,624-3.3%2025-09-30
Centric Wealth Management$920.001.55%574,898+1,500+0.26%2025-09-30
Geode Capital Management, Llc$434.000.73%271,056+48,873+22%2025-09-30
Marshall Wace, Llp$177.000.3%110,467+94,302+583.37%2025-09-30
Blackrock, Inc.$168.000.28%104,857+1,592+1.54%2025-09-30
State Street Corp$121.000.2%75,55000%2025-09-30
Northern Trust Corp$62.000.11%39,03200%2025-09-30
Bridgeway Capital Management, Llc$58.000.1%36,00000%2025-09-30
Centerpoint Advisory Group$25.000.04%15,73000%2025-09-30
Wealth Enhancement Advisory Services, Llc$24.000.04%14,80000%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.